| Trial ID: | L2178 |
| Source ID: | NCT03714594
|
| Associated Drug: |
Dapagliflozin 10mg
|
| Title: |
Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes Mellitus
|
| Interventions: |
DRUG: Dapagliflozin 10mg|DRUG: Saxagliptin 5mg|DRUG: Saxagliptin 5mg + Dapagliflozin 10 mg
|
| Outcome Measures: |
Primary: Glucose Metabolism, To determine the effect of the combination of dapagliflozin (a SGLT2-inhibitor) and saxagliptin (a DPP-4 inhibitor) on pancreatic hormones secretion and endogenous glucose production in Type 2 diabetic subjects through comparison of the effects of co-administration of Saxagliptin and Dapagliflozin vs. Saxagliptin or Dapagliflozin alone., from first day |
|
| Sponsor/Collaborators: |
Sponsor: University of Pisa
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
48
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2018-07-24
|
| Completion Date: |
2022-08-31
|
| Results First Posted: |
|
| Last Update Posted: |
2022-11-08
|
| Locations: |
Department of Endocrinology and Metabolism, University of Pisa, Pisa, 56124, Italy
|
| URL: |
https://clinicaltrials.gov/show/NCT03714594
|
